ArticleScientific reports2026
Enhanced antifungal and cytotoxic potential of essential oils encapsulated in polydopamine nanocapsules against Candida albicans and Pichia kudriavzevii.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral fungal infections, particularly those caused by Candida albicans and Pichia kudriavzevii, pose significant health challenges, especially in immunocompromised individuals. This study systematically investigates the antifungal efficacy, antioxidant, and antiproliferative of essential oils (EOs) from Mentha longifolia and Cupressus macrocarpa, encapsulated in polydopamine (PDA) nanocapsules to enhance their stability and bioactivity. Compositional analysis using gas chromatography-mass spectrometry (GC-MS) identified key bioactive compounds contributing to their antifungal and antioxidant properties. The nanocapsules were further characterized using Fourier-transform infrared spectroscopy (FTIR), Transmission electron microscopy (TEM), dynamic light scattering (DLS), and zeta potential analysis, confirming their successful encapsulation, nanoscale morphology, and surface charge stability. The encapsulated EOs demonstrated significantly enhanced antifungal activity, with lower minimum inhibitory concentrations (MICs) than their non-encapsulated counterparts. Additionally, they exhibited strong antioxidant potential in the DPPH assay and notable cytotoxic effects against MCF-7 and HepG-2 cancer cell lines. TEM provided direct evidence of fungal cell disruption, including chromatin condensation, membrane damage, and cytoplasmic leakage, indicating apoptosis and necrosis. The synergistic interaction between EOs and PDA, confirmed by fractional inhibitory concentration index (FICI) analysis, highlights their potential as effective antifungal agents. These findings strongly support EO-PDA nanocapsules as a promising alternative for treating oral fungal infections while also exhibiting potential anticancer properties.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.